Uncommon tumors and exceptional therapies: Paradox or paradigm?

Molecular Cancer Therapeutics

Volumn 6, Issue 4, 2007, Pages 1175-1179

  Braiteh, Fadi ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BCR ABL PROTEIN; CISPLATIN; CLADRIBINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IDARUBICIN; IMATINIB; LENALIDOMIDE; ORPHAN DRUG; PENTOSTATIN; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN TYROSINE KINASE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; STEM CELL FACTOR;

BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 5Q; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAIRY CELL LEUKEMIA; HUMAN; HYPOTHESIS; INDIVIDUALIZATION; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PATIENT CARE; PREDICTION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; SEMINOMA; UNITED STATES;

ANTINEOPLASTIC AGENTS; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34248204234     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0674     Document Type: Editorial

References (44)

1. Jemal A, Murray T, Ward E, at al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Orphan Drug Act. No. 97-414. 1983. Pub. L.
3. Einhorn LH, Williams SD. Chemotherapy of disseminated seminoma. Cancer Clin Trials 1980;3:307-13.
4. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-80.
5. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 2005;45: 357-84.
6. Shinomura Y, Kinoshita K, Tsutsui S, Hirota S. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J Gastroenterol 2005;40:775-80.
7. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
8. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Mad 2002;346:645-52.
9. Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Mad 2003;138:819-30.
10. Giagounidis AA, Germing U, Strupp C, Hildebrandt B, Heinsch M, Aul C. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 2005; 84:569-71.
11. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3.
12. Annino L, Ferrari A, Giona F, et al. Deoxycoformycin induces longlasting remissions in hairy cell leukemia: clinical and biological results of two different regimens. Leuk Lymphoma 1994;14 Suppl 1:115-9.
13. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-74.
14. Fenaux P, Le Deley MC, Castaigne S, et al.; European APL 91 Group. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993;82:3241-9.
15. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med 1994;120:278-86.
16. Golomb HM, Dodge R, Mick R, et al. Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant α-interferon: a report of CALGB study 8515. Leukemia 1994; 8:2037-40.
17. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon α-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 1995;13:974-82.
18. Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994;14 Suppl 1:121-5.
19. Robak T, Krykowski E, Blasinska-Morawiec M, Urbanska-Rys H. Treatment of patients with hairy cell leukemia with 2-chloro-2′-deoxyadenosine (2-CdA). Arch Immunol Ther Exp (Warsz) 1994;42:25-9.
20. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992;10:1103-11.
21. Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19:3852-60.
22. Wiernik PH, Banks PL, Case DC, Jr., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992;79: 313-9.
23. Ohno R, Yoshida H, Fukutani H, et al.; Leukaemia Study Group of the Ministry of Health and Welfare. Multi-institutional study of all-transretinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993;7:1722-7.
24. Ohno R, Ohnishi K, Takeshita A, et al. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. Leukemia 1994;8 Suppl 3:S64-9.
25. Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res 1990;50:3605-9.
26. Staines A, Cartwright RA. Hairy cell leukaemia: descriptive epidemiology and a case-control study. Br J Haematol 1993;85:714-7.
27. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU. α-Interferon for induction of remission in hairy-cell leukemia. N Engl J Med 1984;310:15-8.
28. Carson DA, Piro LD, Wasson DB, Carrera CJ, Beutler E. Activity of 2-chloro-2′-deoxyadenosine in chronic lymphocytic leukemia, hairy cell leukemia, and autoimmune hemolytic anemia. Adv Exp Med Biol 1989; 253A:427-31.
29. Lill MC, Golde DW. Treatment of hairy-cell leukemia. Blood Rev 1990; 4:238-44.
30. Estey EH, Kurzrock R, Kantarjian HM, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2CdA). Blood 1992;79:882-7.
31. + lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83: 2906-11.
32. Spiers AS, Parekh SJ, Bishop MB. Hairy-cell leukemia: induction of complete remission with pentostatin (2′-deoxycoformycin). J Clin Oncol 1984;2:1336-42.
33. + lymphocytes following deoxycoformycin in interferon-α-resistant hairy cell leukemia: 7-year follow-up. Leukemia 1997;11:42-7.
34. Haffner ME. Adopting orphan drugs-two dozen years of treating rare diseases. N Engl J Med 2006;354:445-7.
35. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149-58.
36. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
37. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366: 1527-37.
38. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501.
39. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
40. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
41. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-500.
42. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55.
43. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-68.
44. Yang SH, Mechanic LE, Yang P, et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2005;116:2106-10.